BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings
- Conditions
- Interventions
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1375
- Registration Number
- NCT06013475
- Locations
- 🇺🇸
Bayer, Whippany, New Jersey, United States
A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 100
- Registration Number
- NCT06010914
- Locations
- 🇯🇵
Many Locations, Multiple Locations, Japan
The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People With Chronic Heart Failure With Reduced Ejection Fraction
- Conditions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1391
- Registration Number
- NCT05974189
- Locations
- 🇩🇪
Bayer, Berlin, Germany
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 404
- Registration Number
- NCT05915728
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
🇨🇳The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 303
- Registration Number
- NCT05915702
- Locations
- 🇺🇸
Halo Diagnostics, Indian Wells, California, United States
🇺🇸Biogenix Molecular, LLC, Miami, Florida, United States
🇺🇸Duke University School of Medicine, Durham, North Carolina, United States
A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 93
- Registration Number
- NCT05915026
- Locations
- 🇺🇸
Halo Diagnostics, Indian Wells, California, United States
🇺🇸Children's Mercy Hospital & Clinics, Kansas City, Missouri, United States
🇺🇸Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension, Cincinnati, Ohio, United States
An Observational Study to Learn More How Chronic Kidney Disease Gradually Changes Over Time in Adults Using Electronic Healthcare Records (CKD Natural History Study)
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 969394
- Registration Number
- NCT05914259
- Locations
- 🇩🇪
Bayer, Wuppertal, Germany
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 220
- Registration Number
- NCT05901831
- Locations
- 🇬🇧
Cardiff and Vale University Health Board - University Hospital of Wales (UHW), Cardiff, United Kingdom
🇺🇸Stanford University | Endocrinology Department - Diabetes Research, Stanford, California, United States
🇺🇸Touro University (TU) - College of Osteopathic Medicine (TUCOM) - California, Vallejo, California, United States
A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- Conditions
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 850
- Registration Number
- NCT05900388
- Locations
- 🇸🇪
Many locations, Multiple Locations, Sweden
A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 102
- Registration Number
- NCT05858164
- Locations
- 🇺🇸
Yale Smilow Cancer Hospital Phase I Unit, New Haven, Connecticut, United States
🇺🇸AdventHealth medical Group Oncology Research at Celebration, Celebration, Florida, United States
🇺🇸Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit, Detroit, Michigan, United States